Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Westwater Resources to Present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22, 2021: https://mms.businesswire.com/media/20210324005153/en/866970/5/4947701_WR_Logo_FA.jpg
Westwater Resources to Present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22, 2021


Westwater Resources, Inc. (NYSE American: WWR), an energy materials development company, today announced it will be presenting at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22, 2021

FG Financial Group SPAC Platform Investment Aldel Financial Completes IPO
FG Financial Group SPAC Platform Investment Aldel Financial Completes IPO


FG Financial Group, Inc. (Nasdaq: FGF) (the “Company”), is pleased to announce today that its first SPAC Platform investment, Aldel Financial (“Aldel”) (NYSE: ADF.U), successfully completed its

ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®: https://mms.businesswire.com/media/20200211005387/en/772640/5/ProtoKinetix_logo_Revised.jpg
ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®


ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced

Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration: https://mms.businesswire.com/media/20200211005387/en/772640/5/ProtoKinetix_logo_Revised.jpg
Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration


ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research

Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced

Westwater Resources to Host a Virtual Non-Deal Roadshow on Wednesday, April 7, 2021: https://mms.businesswire.com/media/20210324005153/en/866970/5/4947701_WR_Logo_FA.jpg
Westwater Resources to Host a Virtual Non-Deal Roadshow on Wednesday, April 7, 2021


Westwater Resources, Inc. (NYSE American: WWR), an energy materials development company, today announced that it will be hosting a Virtual Non-Deal Roadshow on Wednesday, April 7, 2021, at 4:00 PM

Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors


Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced

Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced

Westwater Resources Pilot Program Achieves Production Milestone: https://mms.businesswire.com/media/20210324005153/en/866970/5/4947701_WR_Logo_FA.jpg
Westwater Resources Pilot Program Achieves Production Milestone


Westwater Resources, Inc. (NYSE American: WWR), an energy materials development company, today announced a production milestone at its pilot plant operations at Dorfner Anzaplan’s facilities near

Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis


Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and EVER

Mannatech Reports Fourth Quarter 2020 Financial Results
Mannatech Reports Fourth Quarter 2020 Financial Results


Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of

FG Financial Group, Inc. Reports Fiscal Year 2020 Financial Results and Provides Update to Business Strategy
FG Financial Group, Inc. Reports Fiscal Year 2020 Financial Results and Provides Update to Business Strategy


FG Financial Group, Inc. (Nasdaq: FGF) (the “Company”), a reinsurance and investment management holding company focused on opportunistic collateralized and loss capped reinsurance, while allocating

Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis


Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today

Bango Final Results
Bango Final Results


Bango (AIM: BGO), the data-driven commerce company, today announces its Final Results for the year ended 31 December 2020.



Summary





  • Revenue and profit ahead of expectations and demonstrating



Fuel Tech Reports 2020 Fourth Quarter and Full Year Financial Results: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech Reports 2020 Fourth Quarter and Full Year Financial Results


Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and

The L.S. Starrett Company in Compliance with NYSE Continued Listing Standards
The L.S. Starrett Company in Compliance with NYSE Continued Listing Standards


The L. S. Starrett Company (NYSE: SCX) (Starrett or the Company), a leading manufacturer of high-end precision tools, cutting equipment, and metrology systems for industrial, professional and

Fuel Tech Schedules Fourth Quarter and Full Year 2020 Financial Results and Conference Call: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech Schedules Fourth Quarter and Full Year 2020 Financial Results and Conference Call


Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and

Mannatech Declares Fourth Quarter 2020 Dividend
Mannatech Declares Fourth Quarter 2020 Dividend


Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend

Eyenovia Announces FDA Acceptance of the MydCombi NDA
Eyenovia Announces FDA Acceptance of the MydCombi NDA


Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug

Genprex to Participate in Upcoming March Investor Conferences
Genprex to Participate in Upcoming March Investor Conferences


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that

Fuel Tech, Inc. Announces Closing of $25.8 Million Private Placement Priced At-The-Market: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech, Inc. Announces Closing of $25.8 Million Private Placement Priced At-The-Market


Fuel Tech, Inc. (NASDAQ: FTEK) (or "the Company"), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in

Fuel Tech, Inc. Announces $25.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech, Inc. Announces $25.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules


Fuel Tech, Inc. (NASDAQ: FTEK) (or "the Company"), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it